1,2-bis(phenylsulfonyl)ethane is a white crystalline solid with a melting point of 148-150 °C. It is synthesized by the reaction of phenylsulfonyl chloride with 1,2-dibromoethane in the presence of a base, such as sodium hydroxide. 1,2-bis(phenylsulfonyl)ethane has been studied for its potential use as a building block for the synthesis of various organic compounds, including polymers, pharmaceuticals, and other fine chemicals. It is a useful starting material for the preparation of other sulfonyl-containing compounds, and its unique structural features make it a valuable tool in organic synthesis. For example, it can be used to prepare 1,2-bis(phenylsulfonyl)ethane-1,2-diol, a compound that has been shown to exhibit antimicrobial activity. Additionally, 1,2-bis(phenylsulfonyl)ethane can be used in the preparation of polymers, such as polysulfones. Polysulfones are high-performance polymers with excellent thermal stability, chemical resistance, and mechanical strength. They find applications in various industries, including aerospace, automotive, and electronics. Furthermore, 1,2-bis(phenylsulfonyl)ethane has been used in the synthesis of pharmaceuticals. For example, it has been used to prepare a series of sulfonamide derivatives that exhibit anti-inflammatory and analgesic activity. Overall, 1,2-bis(phenylsulfonyl)ethane is a versatile compound with a wide range of potential applications in organic synthesis, materials science, and pharmaceutical chemistry.'
```
ID Source | ID |
---|---|
PubMed CID | 69036 |
CHEMBL ID | 1888648 |
SCHEMBL ID | 777601 |
MeSH ID | M0557522 |
Synonym |
---|
{[2-(phenylsulfonyl)ethyl]sulfonyl}benzene |
599-94-0 |
mls002637640 , |
nsc2716 |
nsc-2716 |
1,2-bis(phenylsulfonyl)ethane , |
smr001547166 |
2-(benzenesulfonyl)ethylsulfonylbenzene |
HMS3091J09 |
nsc 2716 |
einecs 209-979-0 |
1,1'-(ethane-1,2-diylbis(sulphonyl))bisbenzene |
FT-0606311 |
SCHEMBL777601 |
AKOS024287932 |
ULELOBVZIKJPAC-UHFFFAOYSA-N |
1,2-bis(phenylsulphonyl)ethane |
benzene, 1,1'-[1,2-ethanediylbis(sulfonyl)]bis- |
CHEMBL1888648 |
DTXSID30208613 |
mfcd00041256 |
1,1'-[ethane-1,2-diylbis(sulphonyl)]bisbenzene |
[2-(benzenesulfonyl)ethanesulfonyl]benzene |
AS-59996 |
1,2-bis-(phenylsulfonyl)ethane |
E82005 |
CS-0159991 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Nrf2 | Homo sapiens (human) | Potency | 19.9526 | 0.0920 | 8.2222 | 23.1093 | AID624171 |
67.9K protein | Vaccinia virus | Potency | 1.4125 | 0.0001 | 8.4406 | 100.0000 | AID720579 |
geminin | Homo sapiens (human) | Potency | 22.7265 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 7.9433 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Process | via Protein(s) | Taxonomy |
---|---|---|
hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
protein binding | Glycoprotein hormones alpha chain | Homo sapiens (human) |
follicle-stimulating hormone activity | Glycoprotein hormones alpha chain | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Process | via Protein(s) | Taxonomy |
---|---|---|
extracellular region | Glycoprotein hormones alpha chain | Homo sapiens (human) |
extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
Golgi lumen | Glycoprotein hormones alpha chain | Homo sapiens (human) |
follicle-stimulating hormone complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
pituitary gonadotropin complex | Glycoprotein hormones alpha chain | Homo sapiens (human) |
extracellular space | Glycoprotein hormones alpha chain | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.53) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |